Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange

Stock News

08/28

Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1148206442"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148206442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148206442?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 08:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148206442","market":"sg","top_or_hot":-1,"title":"Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange","media":"Stock News","content":"<p>Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-28 08:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"","article_id":"1148206442","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148206442","pubTimestamp":1787876894,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","BK1574":"生物医药B类股","BK1161":"生物科技","09939":"开拓药业-B","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF","BK1515":"抗疫概念"},"translate_title":"Dizal Pharma向香港联交所重新提交H股上市申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"IPOS":1,"09939":1},"content_text":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}